Effect of Antacids on the Pharmacokinetics of Raltegravir

HIV Infections Clinical Trial

Official title:

Effect of Antacids on the Pharmacokinetics of Raltegravir in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00944307
• Other study ID #: 09-0475
• Status: Completed
• Phase: Phase 1
• First received: July 20, 2009
• Last updated: June 26, 2017
• Start date: July 2009
• Est. completion date: December 2009

Study information

• Verified date: June 2017
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test whether there is a drug interaction between raltegravir (a medicine used to treat the human immunodeficiency virus or HIV) and antacids.

Description:

This study will determine if an interaction occurs between the HIV medicine raltegravir and an antacid. A prior study found an interaction with another medicine like raltegravir called elvitegravir and an antacid. The elvitegravir levels were reduced by half. The same interaction may occur with raltegravir and an antacid based on the structure of this medicine and how it works. When the levels of HIV medications are reduced, people with HIV can "fail" their treatment. The virus can multiply when the drug levels are too low and the medications can stop working. We need to be sure that antacids will not cause this problem with raltegravir.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: December 2009
• Est. primary completion date: December 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Absence of HIV-1 infection as documented by any licensed ELISA test kit within 21 days prior to study entry.

• Age greater than or equal to 18 but less than or equal to 60 years.

• Ability and willingness to give written informed consent.

• Within 30% (+/-) of ideal body weight and total body weight of = 50 kg.

• Hematology, Metabolic Profile, Renal, and Hepatic Function tests all within normal limits.

• Creatine kinase (CK) less than 3 times the upper limit of normal

Exclusion Criteria:

• Pregnancy or breast-feeding.

• Women and men of reproductive potential who are actively engaging in sexual activity or assisted reproductive technology with the intent of pregnancy.

• Allergy/sensitivity to raltegravir.

• Allergy/sensitivity to antacids.

• Active drug or alcohol abuse or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements. While on study, subjects will be instructed not to consume alcohol for 48 hours prior the screening visit, and for the 24 hours preceding the intensive pharmacokinetic (PK) study visits and for 24 hours following the completion of the study visits.

• Any medical condition that, in the opinion of the investigator, would interfere with the subject's ability to participate in this protocol.

• Participation in any investigational drug studies within 30 days prior to study entry.

• History of or active cardiovascular, renal, hematologic, hepatic, neurologic, gastrointestinal, psychiatric, endocrine, or immunologic disease(s). This is inclusive of chronic illnesses such as hypertension, coronary artery disease, arthritis, diabetes, any chronic gastrointestinal conditions that might interfere with drug absorption.

• Use of investigational, prescription, and over-the-counter medications within 14 days of study entry with the following exceptions: aspirin, acetaminophen, ibuprofen, and oral contraceptives

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• raltegravir
raltegravir 400mg orally once
• antacid
aluminum, magnesium, simethicone-containing antacid 30mL orally once

Locations

Country	Name	City	State
United States	University of Colorado Denver	Aurora	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Raltegravir AUC with and without an antacid		0-48 hours
Secondary	Raltegravir Cmax with and without an antacid		0-48 hours